So how did UGA do w/ former 5* SG Kentavious Caldwell-Pope?

888 Views | 4 Replies | Last: 4 yr ago by AlDog
dawgpostsucks
How long do you want to ignore this user?
KCP was the Hoop Dawgs' last 5* prospect prior to Anthony Edwards:

2011-'12: 15-17 overall, 5-11 SEC
2012-'13: 15-17 overall, 9-9 SEC

Note: KCP made the All-SEC Freshman team and merited the conference's player of the year award as a sophomore. The Detroit Pistons then selected him w/ the overall #8 pick in the 2013 NBA Draft.

His career stats: started 60 of 64 games and avg. 33.0 mpg, 15.8 ppg, .415 FG% (.339 from 3-pt range), .752 FT%, 6.1 rpg, 1.5 apg, and 0.4 bpg
Nostradawgus
How long do you want to ignore this user?
About how they did under every year under Fox.

Look, I for one am not defending Crean. But let's be straight - Fox was mediocrity at best that was allowed to over stay his utility.

Crean is recruiting circles around Fox. Verdict still very much out on his X's and O's.

I'm about to the point we should shutter men's basketball and go D1 in men's hockey and soccer.
dawgpostsucks
How long do you want to ignore this user?
Nostradawgus said:

About how they did under every year under Fox.
Fox's record with KCP: 30-34 (46.9%) overall, 14-20 (41.2%) SEC

Fox's record without KCP: 129-99 (56.6%) overall, 63-59 (51.6%) SEC
Dean Legge
How long do you want to ignore this user?
Staff
Fox was an 80-degree day in May.

Not hot enough to complain
Not cold enough to complain.

Something no one remembers
champ1210
How long do you want to ignore this user?
He didn't play the AAU game so he didn't recruit well but he was twice the coach Crean is. At least his teams played defense.
AlDog
How long do you want to ignore this user?
champ1210 said:

He didn't play the AAU game so he didn't recruit well but he was twice the coach Crean is. At least his teams played defense.
In other words Fox got more with less, and Crean gets less with more.
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.